Development of New Drugs in Man: A Review

Turner P. Long term assessment of drug safety and efficacy. JR Soc Med 1984; 77: 93–4.

Anonymous. Antidepressants: Astra's zimeldine withdrawn, because of neurological side effects. The Pharmaceutical Journal 1983; 231: 360.

Dunne JF. A global view of adverse reactions. In: Harcus AW , ed. Risk and regulation in medicine - the fettered physician. London: Association of Medical Advisers in the Pharmaceutical Industry, 1982:137–59.

Food and Drug Administration. Bureau of drugs clinical guidelines. Washington: US Government Printing Office, 1977.

Sheck L Cox C Davis HT Commentary. Success rates in the United States drug development system. Clin Pharmacol Ther 1984; 36: 574–83.

Andrews PA Thompson GM Ward C. A regulatory view of the Medicines Act in the United Kingdom. J Clin Pharmacol 1984; 24: 6–18.

WHO Scientific Group. Assessment of the carcinogenicity and mutagenicity of chemicals. WHO Tech Rep Ser 1974; 546.

WHO Scientific Group. Principles for pre-clinical testing of drug safety. WHO Tech Rep Ser 1966; 341.

Association of the British Pharmaceutical Industry. Guidelines for pre-clinical and clinical testing of new medicinal products. Part I - Laboratory investigations. London: ABPI, 1977.

WHO Scientific Group. Guidelines for evaluation of drugs for use in man. WHO Tech Rep Ser 1975; 563.

Smith RL. Extrapolation of animal results to man. In: Gorrod JW Beckett AT , eds. Drug metabolism in man. London: Taylor and Francis, 1978:97–106.

Blackwell B. For the first time in man. Clin Pharmacol Ther 1972; 13: 812–23.

Association of the British Pharmaceutical Industry. Guidelines for preclinical and clinical testing of new medicinal products. Part 2 - Investigations in man. London: ABPI, 1977.

Orme ML'E . Drug absorption in the gut. Br J Anaesth 1984; 56: 59–67.

WHO Scientific Group. Bioavailability of drugs: Principles and problems. WHO Tech Rep Ser 1974; 536.

Association of the British Pharmaceutical Industry. Bioavailability studies in drug development. London: ABPI, 1977.

Mucklow JC. The use of saliva in therapeutic drug monitoring. Ther Drug Monit 1982; 4: 229–47.

Ryan DM Hodges B Spencer GR Harding SM. Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob Agents Chemother 1982; 22: 995–8.

WHO Scientific Group. Public health and the medical use of ionizing radiation. WHO Tech Rep Ser 1965; 306.

Aronson JK Grahame-Smith DG. Clinical pharmacology. Adverse drug interactions. Br Med J 1981; 282: 288–91.

Sharma BK Santana IA Wood EC Intragastric bacterial activity and nitrosation before during and after treatment with omeprazole. Br Med J 1984; 289: 717–9.

Warrington SJ. Non-invasive assessment of the cardiovascular effects of psychotropic drugs. J Clin Psychiatry 1982; 43: 4–7.

Glassman AH Bigger JT Jr . Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch Gen Psychiatry 1981; 38: 815–20.

Medico-Pharmaceutical Forum. A report by the Forum's working party on clinical trials. London: Medico-Pharmaceutical Forum, 1974.

George CF. The importance of clinical pharmacology in drug development. Clin Sci 1981; 60: 247–50.

Freestone S Silas JH Ramsay LE. Sample size for short-term trials of antihypertensive drugs. Br J Clin Pharmacol 1982; 14: 265–8.

Pocock S. Current issues in the design and interpretation of clinical trials. Br Med J 1985; 290: 39–42.

Joyce CRB . Placebos and other comparative treatments. Br J Clin Pharmacol 1982; 13: 313–18.

Beecher HK. Measurement of subjective responses quantitative effects of drugs. New York: Oxford University Press, 1959.

Schindel L. The placebo dilemma. Eur J Clin Pharmacol 1978; 13: 231–5.

Strom BL Melmon KL. Can post-marketing surveillance help to effect optimal drug therapy? JAMA 1979;242:2420–3.

Alloza JL Lasagna L. Commentary. A comparison of drug product information in four national compendia. Clin Pharmacol Ther 1983; 33: 269–77.

VA Cooperative study group on antihypertensive agents. Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension. Clin Pharmacol Ther 1984; 36: 307–14.

Hollister L Overall JE. Experience with a failed post-marketing drug surveillance program. J Clin Pharmacol 1984; 24: 3–5.

Idanpaan-Heikkila JE. Adverse reactions and postmarketing surveillance. In: Burley DM Binns TB , eds. Pharmaceutical medicine. London: Edward Arnold, 1985;126–48.

Moir DC. Clinical pharmacology. Drug monitoring. Br Med J 1981; 282: 632–4.